Enable Injections and Flex will collaborate on the design, development and production of customized wearable injector systems for pharmaceutical company products and clinical trials.
“Effective design of wearable medical devices requires that we innovate on multiple fronts, pushing the boundaries of wearable technology, medical device development and manufacturing processes,” said Paul Humphries, president of high reliability solutions at Flex. “With their track record of quality and innovation, Enable Injections is an ideal partner in this process.”
According to Enable Injections, the company’s novel injectors – based on pain-free injection technology and preferred by patient panels – provide customers with numerous advantages, including:
•Subcutaneous delivery of up to 50 mL doses of high volume and/or viscous biologics.
•Ability to monitor compliance and capture data utilizing optional Bluetooth connectivity and a mobile app to provide a connected healthcare solution.
•Passive warming of drug product, eliminating the 30-minute wait for refrigerated vials to reach room temperature.
•Automated mixing and reconstitution, reducing formulation time and drug development costs.
•Use of standard vials, cartridges and syringes, and existing container closures.
•Facilitation of in-home therapy, reducing healthcare system costs